Plasmodium falciparum antigens expressed on the surface of infected erythrocytes are important targets of naturally acquired immunity against malaria, but their high number and variability provide the pathogen with a powerful means of escape from host antibodies [1][2][3][4] . Although broadly reactive antibodies against these antigens could be useful as therapeutics and in vaccine design, their identification has proven elusive. Here we report the isolation of human monoclonal antibodies that recognize erythrocytes infected by different P. falciparum isolates and opsonize these cells by binding to members of the RIFIN family. These antibodies acquired broad reactivity through a novel mechanism of insertion of a large DNA fragment between the V and DJ segments. The insert, which is both necessary and sufficient for binding to RIFINs, encodes the entire 98 amino acid collagen-binding domain of LAIR1, an immunoglobulin superfamily inhibitory receptor encoded on chromosome 19. In each of the two donors studied, the antibodies are produced by a single expanded B-cell clone and carry distinct somatic mutations in the LAIR1 domain that abolish binding to collagen and increase binding to infected erythrocytes. These findings illustrate, with a biologically relevant example, a novel mechanism of antibody diversification by interchromosomal DNA transposition and demonstrate the existence of conserved epitopes that may be suitable candidates for the development of a malaria vaccine.
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To identify individuals who may produce antibodies that broadly react with P. falciparum-infected erythrocytes (IEs), we developed an improved mixed agglutination assay (Fig. 1a) . Plasma from adults (n = 557) living in a malaria-endemic region in Kilifi, Kenya, were initially tested in pools of five (Fig. 1b) and then individually for their capacity to agglutinate mixtures of erythrocytes infected with three culture-adapted Kenyan parasite isolates, each stained with a different DNA dye. Most plasma samples formed single-colour agglutinates, but three were able to form mixed-colour agglutinates with at least six isolates (Fig. 1c) .
From two selected donors (C and D) whose plasma formed mixed agglutinates with eight parasite isolates, we immortalized immunoglobulin G (IgG)
+ memory B cells 5 and screened the culture supernatants for the capacity to stain erythrocytes infected with the eight isolates. Surprisingly, most antibodies isolated from these donors stained multiple isolates, with the best antibodies, such as MGC34, MGD21 and MGD39, recognizing all eight isolates tested (Fig. 1d) . Conversely, a few antibodies, such as MGD13, were specific for a single isolate. In all cases, only a fraction of IEs were stained (Fig. 1e ) and this fraction varied with different antibodies, possibly reflecting different clonal expression of the relevant antigen. Overall, these findings show that broadly reactive antibodies against IEs can be generated in response to malaria infection.
We investigated the molecular basis of the broad antibody reactivity by comparing the sequences of the antibodies isolated from the two donors. While the antibodies with narrow reactivity showed classical VDJ organization of the heavy (H) chain gene, all the broadly reactive antibodies (14 from donor C, 13 from donor D) carried a large insert of more than 100 amino acids between their V and DJ segments . In both donors, the core of the inserts encoded an amino acid sequence that was 85-96% identical to the extracellular domain of LAIR1, a collagen-binding inhibitory receptor encoded in the leukocyte receptor locus on chromosome 19 (ref. 6) . However, in each donor, the broadly reactive antibodies used a distinct VH/JH combination (VH3-7/JH6 in donor C and VH4-4/ JH6 in donor D) and had junctions of distinct length between the V, LAIR1 and J segments. In addition, the broadly reactive antibodies from donor D shared a single light (L) chain (VK1-8/JK5), while the antibodies from donor C had one of three different L chains (VK1-5/ JK2, VK4-1/JK2, VL7-43/JL3) (Extended Data Fig. 4 ). All the broadly reactive antibodies carried a high load of somatic mutations spanning the whole V-LAIR1-DJ region. The mutations in the VH segment were used to reconstruct genealogy trees showing a developmental pathway with progressive acquisition of somatic mutations (Fig. 2b, c) . Notably, the trees were consistent with those generated using only the LAIR1 insert or the VL sequence (Extended Data Fig. 5 ). These findings indicate that, within each individual, a single B-cell clone carrying a LAIR1 insert expanded after stimulation by malaria antigens and progressively accrued mutations in the LAIR1, VH and VL regions.
To explore the mechanism that led to the generation of the LAIR1-containing antibodies, we compared complementary DNA and genomic DNA sequences obtained from the antibody-producing B-cell clones (Fig. 2d) . In both donors, the genomic DNA contained a LAIR1 insert that was larger than that found in the corresponding cDNA. In particular, in donor C, the insert comprised not only the 294 base pair (bp) exon encoding the extracellular LAIR1 domain, but also a 190 bp 5′ intronic region of the LAIR1 gene that was partially spliced out in the messenger RNA, and a shorter 23 bp 3′ intronic region that was maintained in the mRNA (Extended Data Fig. 6a ). Donor D had a somewhat different genomic insertion, with larger 5′ (378 bp) and 3′ (60 bp) LAIR1 intronic sequences, and, 5′ of the LAIR1 insertion, an additional sequence of 135 bp corresponding to an intergenic sequence of chromosome 13 (Extended Data Fig. 6b, c) . In this donor, the entire LAIR1 5′ intronic sequence and much of the 5′ chromosome 13 sequence were spliced out in the mRNA (Extended Data Fig. 6d ). The spliced intronic LAIR1 region contained a duplicated 135 bp element with a very high load of somatic mutations (Extended Data Fig. 6e ).
The finding that the inserts were located exactly between the V and DJ segments and were joined to these segments by N nucleotides 1 0 6 | n a T u r E | V O L 5 2 9 | 7 j a n u a r y 2 0 1 6 Letter reSeArCH would suggest that RAG might be involved in the insertion process. Indeed, cryptic recombination signal sequences (RSSs) that followed the 12/23 rule were found flanking both the LAIR1 and the chromosome 13 inserts, although their RSS prediction scores were low and they were not positioned precisely at the ends of the inserts (Extended Data Fig. 7 ). As RAG acts by excising a target DNA sequence, we investigated whether, in B cells making LAIR1-containing antibodies, one of the two LAIR1 alleles on chromosome 19 would be deleted. By sequencing genomic DNA from T cells of donor C, we identified a heterozygous nucleotide site in the chromosome 19 LAIR1 exon sequence. Surprisingly, both alleles were also present in the B cells producing LAIR1-containing antibodies (Extended Data Fig. 8 ), a finding that is inconsistent with the 'cut-and-paste' function of RAG.
To determine the contribution of the mutated VH, VL and LAIR1 domains to the antibody specificity, we generated a panel of constructs and fusion proteins based on the broadly reactive antibody MGD21 (Fig. 3a) . Substitution of the V, J or L chain of MGD21 with that of an unrelated antibody did not affect binding to IEs (Fig. 3b) , suggesting that these elements are dispensable for binding. In contrast, deletion of the LAIR1 insert, or its reversion to the unmutated genomic sequence, led to a complete loss of binding. Furthermore, fusion proteins displaying only the mutated LAIR1 domain bound to IEs, although with lower affinity. To dissect the contribution of the somatic mutations of the LAIR1 insert to antigen binding, we created a set of LAIR1-Fc fusion proteins carrying, in various combinations, the mutations shared by MGD21 with other antibodies of the same clonal family. We tested the mutants for binding to IEs and to collagen, which is the natural ligand of LAIR1. Interestingly, two distinct kinds of mutations were identified: those that reduced collagen binding (P106S and P107R) and those that increased binding to IEs (T67L, N69S and A77T) (Fig. 3c) . Collectively, these findings indicate that the binding of the broadly reactive antibodies to IEs relies mainly on the mutated LAIR1 domain, which evolves under selective pressure to lose collagen binding and gain binding to IEs.
To identify the antigen(s) recognized by the LAIR1-containing antibodies, we generated stable P. falciparum 3D7 lines that were enriched (3D7-MGD21 + ) or depleted (3D7-MGD21 − ) of MGD21 reactivity (Extended Data Fig. 9a ). Western blot analysis showed two specific MGD21-reactive bands of 40-45 kilodaltons (kDa) in erythrocyte ghosts and in MGD21 immunoprecipitates prepared from 3D7-MGD21 + IEs (Fig. 4a) . Analysis of the MGD21 immunoprecipitates by liquid chromatography coupled with mass spectrometry (LC-MS) revealed that a member of the A-type RIFIN family (PF3D7_1400600) was significantly enriched in 3D7-MGD21 + immunoprecipitates as compared to 3D7-MGD21 − immunoprecipitates (log 2 fold change >2; P < 0.01) (Fig. 4b ). PF3D7_1400600 and a second A-type RIFIN (PF3D7_1040300) were also identified in 3D7-MGD21
+ but not in 3D7-MGD21 − ghosts in the absence of immunoprecipitation (Extended Data Fig. 9b ). In contrast, four other RIFINs, including one recently characterized for its capacity to induce rosetting (PF3D7_0100400) 3 , were detected in similar amounts in both 3D7-MGD21 + and 3D7-MGD21 − ghosts. We found that enrichment for 3D7-MGD21 + IEs greatly increased recognition by all the other broadly reactive antibodies from donor D tested and, notably, by two broadly reactive antibodies from donor C (Extended Data Fig. 9c ), suggesting that these antibodies recognize the same antigens. Similar results were obtained with the Kenyan isolate 9605 (Extended Data Fig. 9d, e) .
The binding of the LAIR1-containing antibodies to specific RIFINs was confirmed by the finding that MGD21 stained CHO cells transfected with the candidate antigens PF3D7_1400600 and PF3D7_1040300, but not with irrelevant RIFINs that were similarly expressed (PF3D7_0100400 and PF3D7_0100200) or not detected (PF3D7_1100500) in 3D7-MGD21
+ and 3D7-MGD21 − ghosts (Fig. 4c) . Furthermore, MGD21 and an Fc fusion protein containing the MGD21 LAIR1 domain stained CHO cells transfected with a RIFIN chimaera containing the constant region of PF3D7_0100200 and the variable region of PF3D7_1400600, but not cells transfected with the inverse chimaera (Extended Data Fig. 9f, g ), indicating that MGD21 binds to the variable region. Collectively, these results indicate that the LAIR1-containing antibodies recognize specific members of the RIFIN family in different P. falciparum isolates.
Addition of MGD21 to 3D7 culture did not interfere with parasite growth and did not result in decreased expression of the antigen(s) (Extended Data Fig. 9h, i) . In addition, when tested in a rosette inhibition assay with O + or A + erythrocytes, MGD21 did not show a consistent inhibitory effect (P > 0.1 for both blood groups) Figure 1 | Identification of broadly reactive monoclonal antibodies against IEs. a, Fluorescence microscopy images of single agglutinates (top) and a triple agglutinate (bottom). Scale bar, 50 μm. b, c, Plasma (pooled in groups of five) from immune adults were screened against six parasite isolates using the triple mixed agglutination assay (b). Pools that formed mixed agglutinates with at least five isolates (in red) were further investigated for individual reactivity against an extended panel of eight isolates (c). d, Heat map showing the percentage of IEs of eight parasite isolates stained by monoclonal antibodies isolated from two donors (n = 1). Closely related antibodies are grouped in alternating colours. e, Example of staining of IEs by the broadly reactive antibody MGD55.
Letter reSeArCH (Extended Data Fig. 9j ). In contrast, MGD21, as well as MGC34, could agglutinate erythrocytes infected with 3D7 or the Kenyan isolate 11019 (Extended Data Fig. 9k ). Furthermore, MGD21 showed a strong capacity to opsonize 3D7 IEs for phagocytosis by human monocytes (Fig. 4d) . Opsonization was dependent on an intact Fc, as a mutant lacking Fc receptor binding (MGD21 LALA) did not induce phagocytosis. Similar results were obtained with other broadly reactive antibodies isolated from both donors and with a different parasite isolate (11019) (Extended Data Fig. 9l ), suggesting that these broadly reactive antibodies could be effective in promoting phagocytosis and destruction of IEs in vivo.
Our study opens several questions as to the potential use of RIFINs as targets for passive and active vaccination. RIFINs represent the largest family (~150 genes) of variant antigens expressed on IEs, some of which have been implicated in severe malaria 3 . The LAIR1-containing antibodies have potent agglutinating and opsonizing activity, which would be consistent with their role in decreasing the burden of IEs in vivo by enhancing parasite clearance. However, the staining of only a fraction of IEs by the LAIR1-containing antibodies is consistent with the clonal expression of RIFINs 3 and suggests that these antibodies may not be sufficient to take full control of the infection. It will be interesting to determine whether the LAIR1-containing antibodies recognize RIFINs that are expressed at other stages of the parasite life cycle, such as sporozoites, merozoites and gametocytes 7, 8 , which may create new opportunities for vaccine design.
The unusual architecture of the LAIR1-containing antibodies illustrates a novel mechanism of interchromosomal DNA transposition that can contribute to antibody diversification (Extended Data Fig. 10 ). The precise location of the LAIR1 and chromosome 13 inserts between the V and DJ segments, as well as the presence of N nucleotides and cryptic 12/23 RSSs at the ends of the inserts, would be compatible with a role for the RAG enzyme. RAG has been implicated in interchromosomal genomic rearrangements at cryptic RSSs outside the immunoglobulin and T-cell antigen receptor (TCR) loci 9, 10 , and in the formation of chromosomal translocations found in human lymphomas 11 . However, RSSs are frequently found in the genome and are generally inactive, according to recent data 12, 13 . Furthermore, the conservation of the two LAIR1 alleles in B cells producing LAIR1-containing antibodies is inconsistent with a RAG-mediated 'cut-and-paste' pathway and suggests a new mechanism by which LAIR1 DNA is duplicated. This mechanism may involve reverse transcription of pre-mRNA and subsequent insertion of the duplicated fragment to repair a DNA double-strand break, as recently proposed 14 . It is also possible that gene conversion 15 or AID-dependent genomic instability caused by chronic Plasmodium infection 16 may contribute to the production of LAIR1-containing antibodies. AID can lead to insertions and deletions of multiple codons in the V genes, which contribute to the specificity of the antibody in the context of the whole V gene 17, 18 . Nevertheless, to the best of our knowledge, these insertions are distributed over the whole V-gene sequence, are of smaller size and cannot be traced back to a particular genomic sequence as in the case of LAIR1. VH3-7  MGC1  LAIR1   90  100  110  120  130  140  150  160   VH3-7  MGC1  LAIR1   170  180  190  200  210  220  230  240   D2-21/JH6  MGC1  LAIR1   1  10  20  30  40  50  60  70  80   VH4-4  MGD21  LAIR1   90  100  110  120  130  140  150 10 (7) 10 (5) 24 (15) 39 (21) 18 (10) 1 (1) 11 (5) 6(5) 13 (5) 10 ( 25 (15) 7 (3) 6 (2) 5 (1) 8 (8) 29 (16) 30 (17) 3(1) 8(6) 29 (21) 25 (15) 22 (15) 3 (1) 13 ( (38) 4 (2) 8 (4) 9 (5) 14 (12) 47 (25) 4 (4) 32 (18) 7 (5) 7 (6) 3(1) 11(6) 8 (5) 22 (12) 39 (21) 7 (5) T67L  N69S  A77T  P106S  P107R  T67L/N69S  T67L/A77T  T67L/P107R  N69S/A77T  N69S/P107R  P106S/P107R  T67L/N69S/A77T  T67L/N69S/P107R  T67L/P106S/P107R  N69S/P106S/P107R  A77T/P106S/P107R  T67L/N69S/P106S/P107R  T67L/N69S/A77T/P107R  T67L/N69S/A77T/P106S/P107R   T67   N69   A77   P106 + IEs versus from 3D7-MGD21 − IEs (from n = 4 independent experiments). Statistical significance was evaluated by Welch tests (P < 0.01 for PF3D7_1400600). c, MGD21 and BKC3 staining of CHO cells transfected with a specific (PF3D7_1400600) or an irrelevant (PF3D7_0100200) RIFIN (representative of n = 5 independent experiments). d, Opsonic phagocytosis of 3D7-MGD21 + IEs by monocytes (n = 3 for MGD21, MGD21 LALA and BKC3, n = 2 for others). The IEs were stained with 4′,6-diamidino-2-phenylindole (DAPI), which was quantified in monocytes as a measure of phagocytosis. MGD21 LALA is a mutant of MGD21 lacking Fc receptor binding. IEs from three parasite isolates were separately stained with 10 μg ml −1 DAPI, 200 μg ml −1 ethidium bromide or 6.7× SYBR Green I for 1 h at room temperature. The stained parasites were washed five times, mixed in equal proportions, and diluted to a 5% haematocrit in incomplete RPMI medium. Ten microlitres of the parasite mixture was rotated with 2.5 μl of adult plasma for 1.5 h at room temperature, and agglutinates formed were examined by fluorescence microscopy. In the primary screen, pools of five adult plasma were tested against six Kenyan isolates (in two separate reactions). Pools that formed mixed-colour agglutinates were identified and individual plasma within these pools were tested against nine isolates using the same assay. A single isolate (10668) was not detected in mixed agglutinates formed by any of the plasma and was therefore excluded from the study. Two adults (donors C and D) with plasma that formed mixed agglutinates with eight parasite isolates were selected for monoclonal antibody isolation and, following further informed consent, an additional blood sample was taken from each individual in February 2014. B-cell immortalization and isolation of monoclonal antibodies. IgG + memory B cells were isolated from cryopreserved peripheral blood mononuclear cells (PBMCs) by magnetic cell sorting with mouse anti-CD19-PECy7 antibodies (BD Pharmingen, catalogue no. 341113) and mouse anti-PE microbeads (Miltenyi Biotec, catalogue no. 130-048-081), followed by flow cytometry sorting for IgG ) and irradiated feeder cells as described previously 5 . Two weeks post-immortalization, culture supernatants were tested for the ability to stain IEs from eight parasite isolates by flow cytometry. Cryopreserved IEs were thawed, stained with 10× SYBR Green I, and incubated with the B-cell supernatants for 1 h at 4 °C. Antibody binding was detected using 2.5 μg ml −1 of goat Alexa Fluor 647-conjugated anti-human IgG (Jackson ImmunoResearch, . Reactivity was calculated based on the percentage of late-stage parasites (high SYBR Green) recognized by each antibody. Sequence analysis of antibody cDNA and genomic DNA. cDNA was synthesized from selected B-cell cultures and both heavy chain and light chain variable regions (VH and VL) were sequenced as previously described 22 . The usage of VH and VL genes and the number of somatic mutations were determined by analysing the homology of VH and VL sequences of monoclonal antibodies to known human V, D and J genes in the IMGT database 23 . Genomic DNA was isolated from two B-cell lines of donor C and one B-cell line of donor D with a commercial kit (QIAGEN), and antibody-encoding sequences were amplified and sequenced with primers specific for the V and J regions of the given antibody. Sequences were aligned with ClustalW2 (ref. 24) . Potential cryptic RSS sites were identified using the RSSsite web server 25 . To determine the heterozygosity of LAIR1 on chromosome 19, the following primers were used to perform PCRs on genomic DNA: LAIR1_INTR_FW1, GGCGGTGGGCACTCAGGTTC; LAIR1_INTR_REV1, CACAGGCAGTCACCGGGTCTAGG; LAIR1_INTR_ FW2, GGATGCACCATGTCACCCAGTCCTGG. Genomic DNA isolated from PHA-and IL-2-stimulated T cells from donor C was used as a control for sequence analysis. Immunoglobulin lineage and genealogy analysis. Unmutated common ancestor (UCA) sequences of the VL region were inferred with Antigen Receptor Probabilistic Parser (ARPP) UA Inference software, as previously described 26 . UCA sequences of the VH region were constructed using IMGT/V-QUEST 23 and the genomic insert sequences. Nucleotide sequences of the mutated antibodies and the UCA were aligned using ClustalW2 (ref. 24), and phylogenetic trees were generated with the DNA Maximum Likelihood program (Dnaml) of the PHYLIP package, version 3.69 (refs 27, 28 of type I recombinant human collagen (Millipore, catalogue no. CC050), blocked with 1% bovine serum albumin (BSA) and incubated with titrated antibodies, followed by AP-conjugated goat anti-human IgG, Fcγ fragment specific (Jackson ImmunoResearch, catalogue no. 109-056-098). Plates were then washed, substrate (p-NPP, Sigma) was added and plates were read at 405 nm. Immunoprecipitation and LC-MS. Erythrocyte ghosts were prepared by hypotonic lysis with 1× PBS diluted 15-fold in water, and ghost membranes were dissolved in a reducing lysis buffer containing 2% SDS, 10 mM dithiothreitol (DTT), 10 mM HEPES pH 8, sonicated and boiled. Solubilized proteins were alkylated with iodoacetamide (final concentration 55 μM) for 30 min at room temperature and precipitated with 80% acetone overnight at 4 °C. The precipitates were resuspended in urea and digested with trypsin. For immunoprecipitation experiments, IEs were sonicated and dissolved in 7.2 M urea in RIPA buffer (1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate in HBS pH 7.4). The samples were centrifuged and supernatants were diluted 6.7-fold with RIPA buffer containing a protease inhibitor cocktail (Sigma-Aldrich) and incubated with 10 μg of MGD21 or BKC3 overnight at 4 °C. Next, Protein G-Sepharose beads (GE Healthcare) were added and samples were incubated for 1 h at 4 °C. The beads were washed four times and immunoprecipitates were digested directly on the beads with trypsin. After trypsin digestion, peptides were analysed on a Q-Exactive instrument at the Functional Genomics Center in Zurich. Raw files were analysed using the MaxQuant software 29, 30 and MS/MS spectra were searched against the human and P. falciparum 3D7 UniProt FASTA databases (UP000005640 and UP000001450). Peptide identifications were matched across several replicates. Subsequent data analysis was performed in the R statistical computing environment. Missing values were imputed with a normal distribution around an LFQ value of 21. Statistical significance was evaluated by Welch tests. Western blots. Ghosts and immunoprecipitates were dissolved in 2× SDS sample buffer (Bio-Rad) and run on a 12% polyacrylamide gel under non-reducing conditions. The proteins on the gel were transferred onto a PVDF membrane, which was blocked with 5% milk in TBS with 0.1% Tween (TBST) for 1 h at room temperature. The membrane was incubated with 5 μg ml −1 MGD21 overnight at 4 °C, washed with TBST, and developed with horseradish peroxidase (HRP)-conjugated sheep anti-human IgG (GE Healthcare, catalogue no. NA933) used in combination with a chemiluminescent substrate. Expression of RIFINs. Genes encoding the A-RIFINs PF3D7_1400600, PF3D7_1040300, PF3D7_0100400, PF3D7_0100200 and PF3D7_1100500 were produced by gene synthesis (Genscript) and cloned into the pDisplay vector (Invitrogen), which contains a haemagglutinin (HA) tag, as previously described 3 . RIFIN chimaeras containing the constant region of PF3D7_1400600 (residues 38-146) and the variable region of PF3D7_0100200 (residues 151-288) (PF3D7_1400600c_0100200v), or containing the constant region of PF3D7_0100200 (residues 42-150) and the variable region of PF3D7_1400600 (residues 147-325) (PF3D7_0100200c_1400600v), were generated. The pDisplay Letter reSeArCH constructs were transiently transfected into CHOK1-SV cells (GS-System, Lonza) using PEI. Cell lines were routinely tested for mycoplasma contamination. Briefly, 1 day before transfection, CHOK1-SV cells were seeded at 0.5 × 10 6 cells ml −1 in 30 ml CD-CHO medium (Invitrogen) supplemented with 2 mM l-glutamine in 125 ml Erlenmeyer flasks (Corning). On the day of transfection, 20 μg DNA was diluted in OPTI-PRO SFM Medium (Invitrogen) and mixed with 200 μg PEI for 20 min at room temperature. The DNA-PEI complexes were added to the cells, which were cultured in a CO 2 shaker incubator at 37 °C, 135 r.p.m. After 72 h, the expression of RIFINs and their recognition by the LAIR1-containing antibodies were tested by flow cytometry. Briefly, 5 μg ml −1 of rabbit anti-HA tag and 2 μg ml −1 of MGC or MGD antibodies were added to the RIFIN-transfected cells. Antibody binding was detected by 5 μg ml −1 of Alexa Fluor 488-conjugated goat anti-rabbit IgG (Life Technologies, catalogue no. A11034) and 2.5 μg ml −1 of Alexa Fluor 647-conjugated goat anti-human IgG (Jackson ImmunoResearch, catalogue no. 109-606-170). Dead cells were excluded by staining with 7-AAD (BD Biosciences).
Inhibition of parasite growth. 3D7-MGD21
+ (5% parasitaemia, ring stage) was cultured with various concentrations of MGD21 or BKC3 for 2 days. After 2 days, 10× SYBR Green I was added to aliquots of each culture and parasitaemia was quantified by flow cytometry. The remaining parasites in each culture were washed to remove the antibodies and incubated for 1 day to allow the parasites to reach the late trophozoite/schizont stage. MGD21 recognition of these cultures was detected using 2.5 μg ml −1 of Alexa Fluor 647-conjugated goat anti-human IgG (Jackson ImmunoResearch, catalogue no. 109-606-170).
Inhibition of rosetting. 9605-MGD21
+ IEs at the late trophozoite/schizont stage were purified from uninfected erythrocytes and ring-stage parasites using a magnetic column (Miltenyi Biotec) and were resuspended in culture medium with 10% human serum. The purified IEs were incubated with 10 μg ml −1 of MGD21 or BKC3 for 1 h at 4 °C, mixed with O + erythrocytes or A + erythrocytes in a 1:20 ratio, and incubated for 30 min at room temperature to allow rosetting to occur. The IEs were stained with 10× SYBR Green I, and the number of rosettes formed by at least 200 IEs was counted by fluorescence microscopy to calculate the rosetting rate.
Agglutination with monoclonal antibodies. 3D7-MGD21
+ and 11019-MGD21 + IEs(4-5% parasitaemia) were diluted to a 3% haematocrit in a 5× SYBR Green I solution containing 5 μg ml −1 of the test monoclonal antibody. Each sample was rotated for 1 h at room temperature and subsequently examined by fluorescence microscopy.
Opsonic phagocytosis by monocytes. IEs were stained with 10 μg ml −1 DAPI for 30 min at room temperature, washed four times and run on a magnetic column (Miltenyi Biotec) to purify late-stage parasites. The purified parasites were opsonized with serially diluted antibodies for 1 h at 4 °C. Monocytes were isolated from fresh PBMCs of healthy donors using mouse anti-CD14 microbeads (Miltenyi Biotec, and mixed with the opsonized parasites in a 1:2 ratio for 1 h at 37 °C. Extracellularly bound, non-internalized IEs were lysed by treatment with red blood cell lysis solution (Miltenyi Biotec) for 10 min at room temperature. The cells were stained with mouse anti-CD14-PECy5 (Beckman Coulter, catalogue no. A07765) and analysed by flow cytometry. The mean fluorescence intensity (MFI) of DAPI in CD14
+ cells was used as a measure of phagocytosis of IEs by monocytes. Statistics. The Wilcoxon signed-rank test was used for statistical comparisons of pairs of data groups in rosetting experiments. No statistical methods were used to predetermine sample size. 
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UCA G A G G T G C A G C T G G T G G A G T C T G G G G G A G G C T T G G T C C A G C C T G G G G G G T C C C T G A G A C T C T C C T G T G C A G C C T C T G G A T T C A C C T T T A G T A G C T A T T G G A T G A G C T G G G T C C G C C A G G C T C C

UCA G G G A A G G G G C T G G A G T G G G T G G C C A A C A T A A A G C A A G A T G G A A G T G A G A A A T A C T A T G T G G A C T C T G T G A A G G G C C G A T T C A C C A T C T C C A G A G A C A A C G C C A A G A A C T C A C T G T A T C T G C
UCA A T G A A C A G C C T G A G A G C C G A G G A C A C G G C T G T G T A T T A C T G T G T G A G A G A C A G A T T C T G C A G T G A T ---G A G A A T C A C A T G C A C G T A G A A G A A G A T C T G C C C A G A C C C T C C A T C T C G G C T G
UCA C C A G G C A C C G T G A T C C C C C T G G G G A G C C A T G T G A C T T T C G T G T G C C G G G G C C C G G T T G G G G T T C A A A C A T T C C G C C T G G A G A G G G A G A G T A G A T C C A C A T A C A A T G A T A C T G A A G A T G T G T C T
UCA C A A G C T A G T C C A T C T G A G T C A G A G G C C A G A T T C C G C A T T G A C T C A G T A A G T G A A G G A A A T G C C G G G C T T T A T C G C T G C A T C T A T T A T A A G C C C C C T A A A T G G T C T G A G C A G A G T G
UCA G A G C T G C T G G T G A A A G G T G A G G A C G T C A C C T G G G C C C T G T T A A C G T A T T G T G G T G G T G A T G G A G A G G A A T C C G A C T A C T A C A T G G A C G T C T G G G G C A A A G G G A C C A C G G T C A C C G T C T C C T C
UCA G G G A A G G G G C T G G A G T G G A T T G G G G A A A T C T A T C A T A G T G G G A G C A C C A A C T A C A A C C C G T C C C T C A A G A G T C G A G T C A C C A T A T C A G T A G A C A A G T C C A A G A A C C A G T T C T C C C T G A A G C T G A G C
UCA T C T G T G A C C G C C G C G G A C A C G G C C G T G T A T T A C T G T G C G A G A G T T T C T C C A T T C A A G T C T C A G ---A G G G A C A C C A A A G A T C T G C C C A G A C C C T C C A T C T C G G C T G A G C C A G G C A C C G T G A T C C
UCA C T G G G G A G C C A T G T G A C T T T C G T G T G C C G G G G C C C G G T T G G G G T T C A A A C A T T C C G C C T G G A G A G G G A G A G T A G A T C C A C A T A C A A T G A T A C T G A A G A T G T G T C T C A A G C T A G T C C A T C T G A G T C
UCA G A G G C C A G A T T C C G C A T T G A C T C A G T A A G T G A A G G A A A T G C C G G G C C T T A T C G C T G C A T C T A T T A T A A G C C C C C T A A A T G G T C T G A G C A G A G T G A C T A C C T G G A G C T G C T G G T G A A A G G T G A G G A C
UCA G T C A C C T G G G C C C T G C C C C A G T C T C A G C T C G A C C C T C G A G C T T G T C C C C A G G A A G A T T T G A A C A T T A G T A C C G A T A T T T A C T A C A T G G A C G T C T G G G G C A A A G G G A C C A C G G T C A C C G T C T C C T C A
UCA C A G G T G C A G C T G C A G G A G T C G G G C C C A G G A C T G G T G A A G C C T T C G G G G A C C C T G T C C C T C A C C T G C G C T G T C T C T G G T G G C T C C A T C A G C A G T A G T A A C T G G T G G A G T T G G G T C C G C C A G C C C
VH4-4 Junction Chr13
LAIR1 exon JH6 LAIR1 intron MGC29 . . G . . . . . . . . . . . . . . . . . . T . T . . T . . . . . . . A . . T . . A . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A  MGC35 . . G . . . . . . . . . . . . . . . . . . T . T . . T . . . . . . . A . . T . . A . . . A . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A  MGC4 . MGC36 . . G . . . . . . . . . . . . . . . . . . T . T . . T . . . . . . . . . . T . . A . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A  MGC28 . C . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . C . . . A . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . G . . . . . . A . A C A  MGC33 . C . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . C . . . A . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . G A A G  MGC34 .. . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . . T . . . . . . . . . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  MGC5 . MGC29 .. . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . C . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  MGC35 .. . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . C . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MGC36 .. . . . . . . . . . . . . . . . . . . C . . . . . . . . . . . . . . . . C . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  MGC28 .. . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . G . . . . . . . . G . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . .  MGC33 .. . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . G . . . . . . . . G . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A G C A G  MGC34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G . . . . . C . C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . G . . . . . G . . . . . . . . . . . . . 5 (1) 6(3) 14 (9) 3 (2) 1 (1) 11 (7) 1 (1) 9(5) 6 (2) 12 (7) 9 (4) 8 (5) 3 (3) 17 (11) 11 (9) 5 (2) 2 ( 15 (9) 18 (12) MGD 41 2 (2) 2 (2) 1 (1) 16 (6) 6(3) 1 (1) 7 (4) 4 (1) 15 (7) 6 (4) 16 (10) 15 (6) UCA Donor D LAIR1
UCA L G S H V T F V C R G P V G V Q T F R L E R E S R S T Y N D T E D V S Q A S P S E S E A R F R I D S V S E G N A G P Y R C I Y Y K P P K W S E Q S D Y L E L L V K G E D V T W A L P Q S Q L D P R A C P Q E D L N I S T D I Y Y M D V W G K G T T V T V S S
UCA E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y W M S W V R Q A P G K G L E W V A N I K Q D G S E K Y Y V D S V K G R F T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C V R D R F C S D -E N H M H V E E D L P R P S I S A E
UCA V I P L G S H V T F V C R G P V G V Q T F R L E R E S R S T Y N D T E D V S Q A S P S E S E A R F R I D S V S E G N A G L Y R C I Y Y K P P K W S E Q S D Y L E L L V K G E D V T W A L L T Y C G G D G E E S D Y Y M D V W G K G T T V T V S S
UCA Q V Q L Q E S G P G L V K P S G T L S L T C A V S G G S I S S S N W W S W V R Q P P G K G L E W I G E I Y H S G S T N Y N P S L K S R V T I S V D K S K N Q F S L K L S S V T A A D T A V Y Y C A R V S P F K S Q -R D T K D L P R P S I S A E P G T V I P
UCA A A A C C T G G A C A A G C A C C C A G G G C A C T G A T T T A T A G T A C A A G C A A C A A A C A C T C C T G G A C C C C T G C C C G G T T C T C A G G C T C C C T C C T T G G G G G C A A A G C T G C C C T G A C A C T G T C A G G T G T G
UCA C A G C C T G A G G A C G A G G C T G A G T A T T A C T G C C T G C T C T A C T A T G G T G G T G C T C A G C C T T G G G T G T T C G G C G G A G G G A C C A A G C T G A C C G T C C
UCA C A G A C T G T G G T G A C T C A G G A G C C C T C A C T G A C T G T G T C C C C A G G A G G G A C A G T C A C T C T C A C C T G T G C T T C C A G C A C T G G A G C A G T C A C C A G T G G T T A C T A T C C A A A C T G G T T C C
UCA G A C A T C G T G A T G A C C C A G T C T C C A G A C T C C C T G G C T G T G T C T C T G G G C G A G A G G G C C A C C A T C A A C T G C A A G T C C A G C C A G A G T G T T T T A T A C A G C T C C A A C A A T A A G A A C T A C T T A G
UCA T G G T A C C A G C A G A A A C C A G G A C A G C C T C C T A A G C T G C T C A T T T A C T G G G C A T C T A C C C G G G A A T C C G G G G T C C C T G A C C G A T T C A G T G G C A G C G G G T C T G G G A C A G A T T T C A C T C T C
UCA A T C A G C A G C C T G C A G G C T G A A G A T G T G G C A G T T T A T T A C T G T C A G C A A T A T T A T A G T A C T C C G T A C A C T T T T G G C C A G G G G A C C A A G C T G G A G A T C A
UCA G A C A T C C A G A T G A C C C A G T C T C C T T C C A C C C T G T C T G C A T C T G T A G G A G A C A G A G T C A C C A T C A C T T G C C G G G C C A G T C A G A G T A T T A G T A G C T G G T T G G C C T G G T A T C A G C A G
UCA G G G A A A G C C C C T A A G C T C C T G A T C T A T A A G G C G T C T A G T T T A G A A A G T G G G G T C C C A T C A A G G T T C A G C G G C A G T G G A T C T G G G A C A G A A T T C A C T C T C A C C A T C A G C A G C C T G C
UCA G A T G A T T T T G C A A C T T A T T A C T G C C A A C A G T A T A A T A G T T A T T C A T A C A C T T T T G G C C A G G G G A C C A A G C T G G A G A T C
UCA G C C A T C C G G A T G A C C C A G T C T C C A T C C T C A T T C T C T G C A T C T A C A G G A G A C A G A G T C A C C A T C A C T T G T C G G G C G A G T C A G G G T A T T A G C A G T T A T T T A G C C T G G T A T C A G C A
UCA G G G A A A G C C C C T A A G C T C C T G A T C T A T G C T G C A T C C A C T T T G C A A A G T G G G G T C C C A T C A A G G T T C A G C G G C A G T G G A T C T G G G A C A G A T T T C A C T C T C A C C A T C A G C T G C C T G C
UCA G A A G A T T T T G C A A C T T A T T A C T G T C A A C A G T A T T A T A G T T A C C C T C C G G A C T T C G G C C A A G G G A C A C G A C T G G A G A T T A
6 (4) 2 (1) 16 (6) 28 (17) 18 (10) MGD 41 2 (1) 5 (3) 1 (1) 11 (6) 10 (3) 2 (1) 12 (7) 3 (0) 24 (14) 12 (8) 6 (2) 15 (9) 16 (8) UCA Donor D VL 
